Ublituximab Treatment is Associated with a Significant Proportion of Patients Achieving No Evidence of Disease Activity (NEDA): Results from the Ultimate I and Ultimate II Phase 3 Studies of Ublituximab vs Teriflunomide in Relapsing Multiple Sclerosis (RMS)

Download

Drug Category: Array

Conference Category: Array

Lead Author: Alvarez E, et al.

Published Date: 03/04/2022

Download Link: /wp-content/uploads/2022/04/Alvarez_NEDA_AAN_2022.pdf

Download Text: Download

Popup Confirmation?:

site-sidebar-layout: default

ast-site-content-layout: default

site-content-style: default

site-sidebar-style: default

theme-transparent-header-meta: default

stick-header-meta: default

astra-migrate-meta-layouts: set